IMR Press / FBE / Volume 2 / Issue 3 / DOI: 10.2741/E167

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Phytate levels and bone parameters: A retrospective pilot clinical trial

Show Less
1 Gestion Sanitaria de Mallorca (GESMA). Servicio de Prevencion de Riesgos Laborales, Spain
2 Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS), University of Balearic Islands; CIBER Fisiopatologia de la Obesidad y Nutricion (CB06/03), Instituto de Salud Carlos III, Spain
3 Administracion de les Illes Balears. Servicio de Prevencion de Riesgos Baleares, Spain
4 Consell Insular de Mallorca, Servicio de Medicina del Deporte, Spain
5 Correos Valencia, Servicio Medico, Spain
Front. Biosci. (Elite Ed) 2010, 2(3), 1093–1098;
Published: 1 June 2010

This study evaluated the relationship between phytate urinary levels and bone characteristics in a large population of postmenopausal women. The study population consisted of 180 postmenopausal women who participated in a descriptive cross-sectional study. A urine sample was collected from each subject to determine phytate levels and the volunteers were divided into two groups according to phytate urinary concentration (i.e., low and high levels). Bone mineral density was determined in the lumbar spine and femoral neck of groups with low and high phytate urinary levels. Urinary levels of phytate were linked to dietary phytate consumption. Hence, bone mineral density values were significantly higher in the lumbar spines and femoral necks of women who consumed high levels of phytate than in women with low urinary phytate concentrations. Higher urinary levels of phytate correlated with higher bone mineral density in the lumbar spine and femoral necks of postmenopausal women. This finding demonstrates the potential use of phytate in the treatment of bone related diseases, as it uses a mechanism of action similar to some bisphosphonates.

Back to top